Cel-Sci Net Income 2006-2021 | CVM

Cel-Sci net income from 2006 to 2021. Net income can be defined as company's net profit or loss after all revenues, income items, and expenses have been accounted for.
Cel-Sci Annual Net Income
(Millions of US $)
2020 $-30
2019 $-22
2018 $-32
2017 $-14
2016 $-12
2015 $-35
2014 $-28
2013 $-9
2012 $-18
2011 $-27
2010 $9
2009 $-41
2008 $-8
2007 $-10
2006 $-8
2005 $-3
Cel-Sci Quarterly Net Income
(Millions of US $)
2021-06-30 $-9
2021-03-31 $-11
2020-12-31 $-8
2020-09-30 $-5
2020-06-30 $-10
2020-03-31 $-9
2019-12-31 $-6
2019-09-30 $-5
2019-06-30 $-12
2019-03-31 $-6
2018-12-31 $1
2018-09-30 $-15
2018-06-30 $-6
2018-03-31 $-5
2017-12-31 $-6
2017-09-30 $-5
2017-06-30 $-4
2017-03-31 $-8
2016-12-31 $4
2016-09-30 $-1
2016-06-30 $-4
2016-03-31 $-9
2015-12-31 $2
2015-09-30 $-10
2015-06-30 $-4
2015-03-31 $-13
2014-12-31 $-8
2014-09-30 $-7
2014-06-30 $-2
2014-03-31 $-13
2013-12-31 $-5
2013-09-30 $-2
2013-06-30 $-5
2013-03-31 $-1
2012-12-31 $-2
2012-09-30 $-3
2012-06-30 $-1
2012-03-31 $-10
2011-12-31 $-4
2011-09-30 $-2
2011-06-30 $-3
2011-03-31 $-15
2010-12-31 $-6
2010-09-30 $-7
2010-06-30 $-1
2010-03-31 $-2
2009-12-31 $19
2009-09-30 $-30
2009-06-30 $-7
2009-03-31 $-2
2008-12-31 $-2
2008-09-30 $1
2008-06-30 $-2
2008-03-31 $-4
2007-12-31 $-2
2007-09-30 $-0
2007-06-30 $-6
2007-03-31 $-3
2006-12-31 $-1
2006-09-30 $-4
2006-06-30 $-1
2006-03-31 $-1
2005-12-31 $-1
2005-09-30 $-0
2005-06-30 $-1
2005-03-31 $-1
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.465B $0.001B
CEL-SCI CORP. was formed to acquire and finance research and development of natural human interleukin-2 (``IL-2``) and lymphokine-related products and processes using the Co.'s proprietary cell culture technologies. The Co.'s proprietary product is sometimes referred to as MULTIKINEn, or buffy-coat interleukins, which is a combination, or ``cocktail`` of IL-2 and certain lymphokines and cytokines. MULTIKINE is a trade name of Co. Since its inception the focus of the Co.'s product development efforts has been on conducting clinical trials to test its proprietary technologies.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $125.527B 7.92
Bio-Rad Laboratories (BIO.B) United States $21.730B 46.31
QIAGEN (QGEN) Netherlands $12.184B 20.63
Biohaven Pharmaceutical Holding (BHVN) United States $8.967B 0.00
Emergent Biosolutions (EBS) United States $2.590B 6.25
Arcus Biosciences (RCUS) United States $2.362B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.929B 0.00
Myovant Sciences (MYOV) United Kingdom $1.832B 0.00
Zymeworks (ZYME) Canada $1.055B 0.00
Ambrx Biopharma (AMAM) United States $0.463B 0.00
SQZ Biotechnologies (SQZ) United States $0.372B 0.00
Enzo Biochem (ENZ) United States $0.159B 15.67